UmbrelLACT Study: Clinical Lactation Study on the Exposure to Medicines Via Human Milk
Launched by UNIVERSITAIRE ZIEKENHUIZEN KU LEUVEN · Sep 11, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The UmbrelLACT Study is a research project aimed at understanding how medicines taken by breastfeeding mothers can affect their breast milk and, ultimately, the babies who are fed with that milk. The main goals of the study are to measure the amount of medication that ends up in breast milk and to estimate how much of that medication a breastfed baby might actually ingest. This information can help ensure the safety of breastfeeding mothers who need to take medications.
To participate in this study, mothers must be at least 18 years old, currently breastfeeding (either exclusively or partially), and taking certain medications. They will need to complete a questionnaire about their and their child's health, track their medication intake for three days, and collect samples of their breast milk over a 24-hour period. Additionally, mothers can choose to provide two blood samples, and give consent for one blood sample from their child. The study is currently recruiting participants, and it’s important for mothers of twins or those under 18 to know that they are not eligible to join. This study aims to provide valuable insights for mothers and healthcare providers about the safety of medications during breastfeeding.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • For breastfeeding women
- • Maternal age: ≥ 18 year
- • Currently exclusively or partially breastfeeding (/expressing milk) at the time of milk sampling
- • Using medicines for any indication, with at least 5 half-lives of the medicine taken
- • Willing to express and collect human milk
- • Signed informed consent to participate and for processing their personal data
- • For infants
- • Gestational age at birth: ≥24 weeks
- • Parental signed informed consent to participate and for processing their personal data
- Exclusion Criteria:
- • Maternal age \<18 years
- • Mother of twins
- • Not meeting the inclusion criteria
About Universitaire Ziekenhuizen Ku Leuven
Universitaire Ziekenhuizen KU Leuven is a leading academic medical center in Belgium, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. Affiliated with KU Leuven, one of Europe’s premier universities, the institution integrates cutting-edge scientific inquiry with high-quality patient care. It plays a pivotal role in the development and implementation of clinical trials, fostering collaboration between researchers, healthcare professionals, and industry partners to translate scientific discoveries into effective treatments. The hospital's multidisciplinary approach ensures comprehensive patient safety and ethical standards, positioning it as a trusted sponsor in the realm of clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Leuven, Vlaams Brabant, Belgium
Patients applied
Trial Officials
Anne Smits, MD PhD
Principal Investigator
Universitaire Ziekenhuizen KU Leuven
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported